Pushed By Rising Costs And Slow Approvals, India’s Dishman Set To Retreat From China
This article was originally published in PharmAsia News
Dishman’s move follows similar moves from Indian peers like Dr. Reddy’s and Ranbaxy, which have also soured on the Chinese market.
You may also be interested in...
Competition To Cooperation: Indian And Chinese Firms Agree On Draft MOU For Partnerships, Investments And GMP Training
MUMBAI - Intense price competition in key developed markets and common concerns for quality products and GMP issues is set to bring India and China together to boost collaborative efforts
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.